Hematology
Conference Coverage
Fitusiran: Great ‘leap forward’ in hemophilia treatment
Cost will be a major consideration if fitusiran is approved for the U.S. market.
News
CDC panel backs mRNA COVID vaccines over J&J because of clot risk
The risk of dying from TTS after a Johnson & Johnson shot is extremely rare.
Conference Coverage
Telemedicine helps SCD patients survive COVID, but more need access
The second COVID-19 wave brought zero deaths and fewer complicated hospitalizations at the largest U.S. adult sickle cell disease center, but care...
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
Conference Coverage
Beta-thalassemia gene therapy achieves lasting transfusion independence
“Seeing the restoration of iron metabolism, it really takes us a step closer to really thinking the term ‘cure’ might truly apply.”
News
Apixaban outmatches rivaroxaban for VTE in study
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Outcomes Research in Review
Evaluation of Intermittent Energy Restriction and Continuous Energy Restriction on Weight Loss and Blood Pressure Control in Overweight and Obese Patients With Hypertension
FDA/CDC
FDA approves new interferon for polycythemia vera
A longer half-life means dosing every 2 weeks, instead of weekly.
News
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...